China's Quanlan raises tens of millions in Series A for brain-therapy devices
What's the deal? Shanghai-based Quanlan Technology has raised a Series A round of tens of millions of yuan to develop non-invasive neuromodulation devices for brain disorders. Green Pine Capital Partners, Green River InvestmentDealroom has a profile for this one. Try Dealroom →, Lingyi Investment, Nanhui Venture CapitalDealroom has a profile for this one. Try Dealroom →, Shanghai Science and Technology Venture Capital, and Xunshang Venture CapitalDealroom has a profile for this one. Try Dealroom → joined the round, announced in November 2026.
What's the endgame? Quanlan builds non-invasive neuromodulation technology aimed at delivering precise "physical drugs" for conditions such as Parkinson's disease and depression. It also supplies high-performance instruments for neuroscience research.
Where's the money going? The company said the proceeds will fund clinical validation of its core devices, regulatory filings, and expansion of its research team.
Why now? The round lands as China's non-invasive neuromodulation sector heats up, with rivals racing toward clinical translation. Kongshanci closed a Series A of tens of millions of yuan this year, while Beizhuo Medical raised nearly US$13.8M in a Pre-A round, both earmarked for clinical pipelines and device registration.
What could go wrong? Quanlan has not disclosed approved products or commercialisation data, and its specific target indications, clinical evidence, and registration progress remain unclear. The funding alone does not confirm clinical or market leadership.
The signal: The spending priorities across the sector show the key hurdle has shifted from technology development to clinical validation and regulatory approval. For Quanlan and its peers, getting devices through trials and registration — not just raising capital — is now the race that matters.
Read more: itbear.com.cn
Image credit: "Free CT scan machine image", public domain (CC0 1.0)